Vaginal douching with polyvinylpyrrolidone iodine (PVP-I) during pregnancy results in maternal iodine overload and increases the iodine content of amniotic fluid. We evaluated the possible effects of this therapy on the thyroid of the fetus by investigating 62 women with a mean duration of amenorrhea of 20 weeks who solicited controlled abortion. Nineteen of them douched daily with PVP-I for 7 consecutive days before abortion (treated group). The other 43 women were not treated (control group). In both groups the iodine content was determined in the fetal thyroid and in amniotic fluid and maternal urine at the time of abortion. In addition, in the treated group the concentrations of iodine were also determined in amniotic fluid and urine before therapy and in urine after 4 days of therapy. There were no differences in the concentrations of iodine in urine and amniotic fluid in the control group and in the treated group before therapy. In the treated group urinary iodine increased from 6.1 ± (SEM) 0.8 µg/dl before therapy to 91 ± 20 µg/dl after 4 days and to 153 ± 60 µg/dl after 7 days of therapy (p < 0.001). In parallel, iodine in amniotic fluid increased from 1.2 ± 0.2 µg/dl before therapy to 3.7 ± 1.3 µg/dl after 7 days (p < 0.05). In both groups the iodine content of the fetal thyroid increased with gestational age. However, it increased more rapidly in the treated group (from 1 to 7.7 µg) than in the control group (from 1 to 2.5 µg), p < 0.05. In conclusion, routine vaginal douching with PVP-I during early pregnancy induces maternal iodine overload and markedly increases the iodine content not only of the amniotic fluid but also of the fetal thyroid, as soon as the trapping mechanism of iodide by the thyroid has started to develop. In view of the well-documented hypersensitivity of the fetal and neonatal thyroid to the blocking effect of excess iodide, the vaginal application of PVP-I is not recommended during pregnancy.

Keywords:
Iodine, nutrition, Iodine, overload, Povidone iodine, therapy by, Thyroid function during pregnancy, Fetal thyroid, iodine content of
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.